Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

A highly significant difference ( P = 0.0001) was observed compared to those receiving placebo ( N = 57) who maintained their mean BMD at the lumbar spine over 5 years of follow-up (−0.1% (95% CI -1.3 to 1.0)).

also in 132,142 other papers